Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Opt Lett ; 36(4): 460-2, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-21326422

ABSTRACT

An innovative spectroscopic technique based on balancing and cancellation of modulated signals induced by two excitation sources is reported. For its practical implementation, we used quartz-enhanced photoacoustic spectroscopy as an absorption-sensing technique and applied the new approach to measure small temperature differences between two gas samples. The achieved sensitivity was 30 mK in 17 s. A theoretical sensitivity analysis is presented, and the applicability of this method to isotopic measurements is discussed.

2.
Blood ; 108(7): 2407-15, 2006 Oct 01.
Article in English | MEDLINE | ID: mdl-16763206

ABSTRACT

The aberrant fusion protein NPM-ALK plays an important pathogenetic role in ALK+ anaplastic large-cell lymphoma (ALCL). We previously demonstrated that Jak3 potentiates the activity of NPM-ALK. Jak3 activation is restricted to interleukins that recruit the common gamma chain (gammac) receptor, including IL-9. NPM-ALK was previously shown to promote widespread lymphomas in IL-9 transgenic mice by unknown mechanisms. We hypothesized that IL-9 plays an important role in ALK+ ALCL via Jak3 activation. Our studies demonstrate the expression of IL-9Ralpha and IL-9 in 3 ALK+ ALCL-cell lines and 75% and 83% of primary tumors, respectively. IL-9 was detected in serum-free culture medium harvested from ALK+ ALCL-cell lines, supporting autocrine release of IL-9. Treatment of these cells with an anti-IL-9-neutralizing antibody decreased pJak3 and its kinase activity, along with pStat3 and ALK kinase activity. These effects were associated with decreased cell proliferation and colony formation in soft agar and cell-cycle arrest. Evidence suggests that cell-cycle arrest can be attributed to up-regulation of p21 and down-regulation of Pim-1. Our results illustrate that IL-9/Jak3 signaling plays a significant role in the pathogenesis of ALK+ ALCL and that it represents a potential therapeutic target for treating patients with ALK+ ALCL.


Subject(s)
Carcinoma/pathology , Gene Expression Regulation, Neoplastic , Interleukin-9/physiology , Lymphoma, Large B-Cell, Diffuse/pathology , Protein-Tyrosine Kinases/biosynthesis , Protein-Tyrosine Kinases/metabolism , Anaplastic Lymphoma Kinase , Animals , Carcinoma/metabolism , Cell Survival , G1 Phase , Humans , Interleukin-9/metabolism , Janus Kinase 3 , Lymphoma, Large B-Cell, Diffuse/metabolism , Mice , Mice, Transgenic , Receptor Protein-Tyrosine Kinases
SELECTION OF CITATIONS
SEARCH DETAIL